US Drug Recall Register

FDA Drug Recalls

2,661 recalls, newest first

Class II · Moderate risk Ongoing

Olopatadine HCl Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0860-2023
Class II · Moderate risk Ongoing

Midazolam Injection

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0859-2023
Class II · Moderate risk Ongoing

Calcitriol Injection 2 mcg/mL

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0858-2023
Class II · Moderate risk Ongoing

Amantadine Hydrochloride Oral Solution USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0857-2023
Class II · Moderate risk Ongoing

Xopenex

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0856-2023
Class II · Moderate risk Ongoing

Vitamin D Supplement Drops

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0855-2023
Class II · Moderate risk Ongoing

Valproic Acid Oral Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0854-2023
Class II · Moderate risk Ongoing

Tropicamide Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0853-2023
Class II · Moderate risk Ongoing

Tobramycin Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0851-2023
Class II · Moderate risk Ongoing

Tobramycin Inhalation Solution USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0850-2023
Class II · Moderate risk Ongoing

Timolol Maleate Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0849-2023
Class II · Moderate risk Ongoing

Sufenta

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0847-2023
Class II · Moderate risk Ongoing

Sodium DIURIL

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0846-2023
Class II · Moderate risk Ongoing

Sodium Chloride Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0845-2023
Class II · Moderate risk Ongoing

Sodium Chloride Ophthalmic Ointment

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0844-2023
Class II · Moderate risk Ongoing

Fentanyl Citrate Injection

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0843-2023
Class II · Moderate risk Ongoing

Ropivacaine Hydrochloride Injection USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0842-2023
Class II · Moderate risk Ongoing

Rifampin Capsules USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0841-2023
Class II · Moderate risk Ongoing

Rifampin Capsules USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0840-2023
Class II · Moderate risk Ongoing

Proparacaine HCl Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0839-2023
Class II · Moderate risk Ongoing

Promethazine HCl Oral Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0838-2023
Class II · Moderate risk Ongoing

Prednisolone Oral Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0836-2023